Apellis Pharmaceuticals
Edit

Apellis Pharmaceuticals

http://apellis.com/
Tags:CADDevelopmentInformationLearnLivingMedtechPlatformScienceWebsite
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. For more information, please visit http://apellis.com.
Location: United States, Massachusetts, Waltham
Member count: 201-500
Total raised: $140.1M
Founded date: 2008

Investors 10

Funding Rounds 3

DateSeriesAmountInvestorsDeal News
10.08.2017Series E$60M-sofinnova....
12.02.2016Series D$47.1M-finsmes.co...
02.12.2014-$33M-vcnewsdail...

Mentions in press and media 34

DateTitleDescriptionCategoryAuthorSource
30.11.2022Prevent Bl...Prevent Blindness declares Dec...--prweb.com/...
26.01.2022Prevent Bl...Prevent Blindness declares Feb...--prweb.com/...
15.12.2021Aspaveli® ...Aspaveli® (pegcetacoplan) appr...--news.cisio...
13.12.2021Apellis an...Improvements demonstrated in t...--marketscre...
13.12.2021Aspaveli®/...Improvements demonstrated in t...--marketscre...
01.12.2021Prevent Bl...National non-profit organizati...--prweb.com/...
12.11.2021Apellis Re...WALTHAM, Mass., Nov. 12, 2021 ...--marketscre...
15.10.2021Swedish Or...Swedish Orphan Biovitrum AB (p...--marketscre...
09.09.2021Apellis Ph...OAKS met the primary endpoint ...--marketscre...
26.07.2021Apellis Ph...Apellis Announces Closing of P...--marketscre...
Show more